Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor

BACKGROUND: Epidermal growth factor receptor (EGFR) alterations are associated with multiple cancers. Current EGFR‐directed therapies have led to increased efficacy but are associated with specific side effects. The antibody‐drug conjugate depatuxizumab mafodotin (depatux‐m) targets EGFR with a mono...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Goss, Glenwood D., Vokes, Everett E., Gordon, Michael S., Gandhi, Leena, Papadopoulos, Kyriakos P., Rasco, Drew W., Fischer, JuDee S., Chu, Katharine L., Ames, William W., Mittapalli, Rajendar K., Lee, Ho‐Jin, Zeng, Jiewei, Roberts‐Rapp, Lisa A., Loberg, Lise I., Ansell, Peter J., Reilly, Edward B., Ocampo, Christopher J., Holen, Kyle D., Tolcher, Anthony W.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5969257/
https://ncbi.nlm.nih.gov/pubmed/29533458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31304
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados